Earnings Call · Q4 FY2021·2022-03-03

Q4 21EPS +100.00%*·Rev n/aQ3 21EPS -100.00%*·Rev n/aQ2 21EPS +100.00%*·Rev n/aQ1 21EPS +61.76%·Rev n/a⚠ consensus missing

PUMA BIOTECHNOLOGY, INC. PBYI

Disclaimer*

Mariann Ohanesian — Investor Relations or Corporate Communications

Alan Auerbach — Chief Executive Officer, President and Chairman of the Board

Jeff Ludwig — Chief Commercial Officer or similar commercial leadership role

Maximo Nougues — Chief Financial Officer

+8.2%1d on move date+9.0% vs SPY3d+19.7%5d+24.5%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more PBYI calls or request research access.

More PBYI calls Browse calls Request research access